exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087767 RNA Name: hsa-miR-140-3p RNA Type: miRNA Chromosome: chr16 Starnd: + Coordinate: Start Site(bp): 69933142 End Site(bp): 69933162 External Links: hsa-miR-140-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ARF3 chr12 48935723 48957487 - ARL1 chr12 101393116 101407772 - ATP6V0D1 chr16 67438014 67481181 - CBL chr11 119206298 119313926 + CDK6 chr7 92604921 92836594 - CLASP1 chr2 121337776 121649587 - CORO1C chr12 108645109 108731596 - CRCP chr7 66114604 66154568 + CRY2 chr11 45847118 45883248 + NDST1 chr5 150485818 150558211 + RNF220 chr1 44405194 44651724 + SLC31A1 chr9 113221544 113264492 + TMEM50A chr1 25338317 25362361 + ZDHHC6 chr10 112424428 112446917 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001880 chr9 110084263 110087285 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000032 chr1 25666964 25669564 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC245014.3 chr1 145281116 145281462 + AL049840.4 chr14 103694516 103695050 - AL356488.2 chr1 109100193 109100619 + KCNQ1OT1 chr11 2608328 2699994 - MIR17HG chr13 91347820 91354579 + MIR29B2CHG chr1 207801518 207879115 - MIR497HG chr17 7015818 7019659 - MIR663AHG chr20 26167817 26251546 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.